Ecromeximab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ecromeximab ?
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target GD3 ganglioside
Clinical data
Legal status ?
Identifiers
CAS number 292819-64-8 N
ATC code None
UNII M76FX2JZRM YesY
Chemical data
Formula ?
Mol. mass 145,255 Daltons
 N (what is this?)  (verify)

Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.[1][2]

This drug was developed by Kyowa Hakko Kogyo Co., Ltd.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab, American Medical Association.
  2. ^ ClinicalTrials.gov NCT00679289 Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma